Evotec
About Us
Careers
News
Resources
Blog
Events
Contact Us
Drug Design and Discovery
Integrated Discovery
Capabilities
Therapeutic Areas
IND Enabling
Integrated Development
Capabilities
Integrated CMC
Integrated Development
Capabilities
INDiGO®
Evotec
Evotec and Almirall enter into research collaboration in the field of dermatological diseases
by
Nerina Coppini
on Sep 17, 2018 8:12:08 AM
Tweet
Collaboration is focused on first-in-class therapies to treat dermatological diseases Collaboration leverages a novel approach to disrupt cell signalling, validated by EVT Innovate
Topics:
Corporate
,
Evotec
,
Almirall
Read More
Most Read
Posts by Topic
Corporate
(49)
Evotec
(21)
Drug Discovery
(15)
Business
(14)
Drug Development
(12)
Drug design and discovery
(9)
Partner Research Organization
(8)
Sanofi
(5)
Strategy
(5)
Antibiotic Resistance
(4)
Celgene
(4)
INDiGO
(4)
IPSC
(4)
New appointments
(4)
Acquisition
(3)
Bayer
(3)
CMC
(2)
Contract Reseach Organization
(2)
Endometriosis
(2)
Gram-negative bacteria
(2)
IND Enabling
(2)
Integrated CMC
(2)
diabetes
(2)
infectious diseases
(2)
2018 results
(1)
Active Pharmaceutical Ingredient
(1)
Almirall
(1)
Antibacterial
(1)
Apeiron
(1)
Aptuit
(1)
Arix Bioscience
(1)
Assay Development
(1)
BRIDGE
(1)
Blood cancer
(1)
CENTOGENE
(1)
CHDI
(1)
CMO award
(1)
Carna Biosciences
(1)
Chronic cough
(1)
Compound Logistics
(1)
Computational Chemistry
(1)
DDup
(1)
Dementia Drug Discovery
(1)
Dermatology
(1)
Ferring
(1)
Finance
(1)
Form selection
(1)
Fred Hutchinson Cancer Research Center
(1)
Haplogen
(1)
Hit Discovery
(1)
Huntington's disease
(1)
Immuneering
(1)
Induced pluripotent stem cells
(1)
Integrated drug discovery
(1)
Investments
(1)
Kidney diseases
(1)
LAB031
(1)
LEO Pharma
(1)
Material Sciences
(1)
Novo Nordisk
(1)
Obesity
(1)
Oncology
(1)
Parkinson's disease
(1)
Phase I
(1)
Regulatory
(1)
Reproductive medicine
(1)
Research collaboration
(1)
Respiratory
(1)
Retinal diseases
(1)
TARGETBCD
(1)
Women's health
(1)
Yumanity Therapeutics
(1)
artificial intelligence
(1)
beta cell replacement
(1)
crispr
(1)
first quarter update
(1)
genomics
(1)
hit identification
(1)
immuno-oncology
(1)
metabolic diseases
(1)
microRNA
(1)
pre-clinical development
(1)
pulmonary diseases
(1)
rare genetic diseases
(1)
small molecule
(1)
technology
(1)
